Blog

Amol Akhade: What Immune Oncology plus chemo combination will u prefer for first line Advanced BTC ?

Amol Akhade/LinkedIn

Dec 11, 2024, 19:39

Amol Akhade: What Immune Oncology plus chemo combination will u prefer for first line Advanced BTC ?

Amol Akhade shared a post on LinkedIn:

“Final Results.

What Immune Oncology plus chemo combination will u prefer for first line Advanced BTC ?

156 votes
As per comments,
Early movers advantage to Topaz ?

Across Atlantic, Durva is more preferred, may be due to earlier approval.
Indian oncologist probably favor pembrolizumab , due to more experience of using it and with better Patient assistance programs , leading to lesser cost .

Overall ,

33 percent preferred Gem cis durva
26 percent will use Gem cis plus pembrolizumab.
24 percent rightly agree that – both are equally good or bad and one can use any of it .
17 percent feel that magnitude of benifit is not much for additional cost and toxicity.

I do feel , as an approved indication, option of Immune Oncology should be given to patients with BTC with disclosure that only some of the patients benifit and more importantly , we don’t know who these patients are .

PdL 1 is most imprecise biomarker in precision Oncology ironically and we need better biomarkers to know which pts will have some long term benifit with additional Immune Oncology.

Off course such online surveys have own limitations.”

Amol Akhade: What Immune Oncology plus chemo combination will u prefer for first line Advanced BTC ?

More posts featuring Amol Akhade.

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.

He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplants.